NCGC00378430

目录号: PL09568 纯度: ≥99%
NCGC00378430 是一种有效的 SIX1/EYA2 相互作用抑制剂。NCGC00378430 部分逆转 SIX1 过表达介导的转录和代谢谱,并逆转 SIX1 诱导的 TGF-β 信号传导和上皮-间质转化 (EMT)。NCGC00378430 在小鼠模型中抑制 SIX1 介导的乳腺癌转移。
CAS No. :920650-00-6
商品编号 规格 价格 会员价 是否有货 数量
PL09568-5mg 5mg ¥973.00 请登录
PL09568-10mg 10mg ¥1475.00 请登录
PL09568-25mg 25mg ¥2705.00 请登录
PL09568-50mg 50mg ¥3805.00 请登录
PL09568-100mg 100mg ¥5125.00 请登录
PL09568-200mg 200mg ¥6875.00 请登录
PL09568-500mg 500mg 询价 询价
PL09568-10mM*1mLinDMSO 10mM*1mLinDMSO ¥4420.00 请登录
PL09568-1 mL x 10 mM (in DMSO) ¥1055.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
*注意事项:下单时请联系销售核实产品价格及货期,避免后续产生不便,感谢支持!
中文名称
NCGC00378430
英文名称
NCGC00378430
英文别名
NCGC00378430;N-[4-methoxy-3-(morpholine-4-sulfonyl)phenyl]-3-(1H-pyrrol-1-yl)benzamide;s9677;Z95624024;N-(4-Methoxy-3-(morpholinosulfonyl)phenyl)-3-(1H-pyrrol-1-yl)benzamide;N-(4-methoxy-3-morpholin-4-ylsulfonylphenyl)-3-pyrrol-1-ylbenzamide;N-[4-Methoxy-3-(4-morpholinylsulfonyl)phenyl]-3-(1H-pyrrol-1-yl)benzamide (ACI)
Cas No.
920650-00-6
分子式
C22H23N3O5S
分子量
441.50
包装储存
Powder -20°C 3 years;4°C 2 years
详情描述
NCGC00378430 是一种有效的 SIX1/EYA2 相互作用抑制剂。NCGC00378430 部分逆转 SIX1 过表达介导的转录和代谢谱,并逆转 SIX1 诱导的 TGF-β 信号传导和上皮-间质转化 (EMT)。NCGC00378430 在小鼠模型中抑制 SIX1 介导的乳腺癌转移。
产品详情
NCGC00378430 是一种有效的 SIX1/EYA2 相互作用抑制剂。NCGC00378430 部分逆转 SIX1 过表达介导的转录和代谢谱,并逆转 SIX1 诱导的 TGF-β 信号传导和上皮-间质转化 (EMT)。NCGC00378430 在小鼠模型中抑制 SIX1 介导的乳腺癌转移。
生物活性
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model.
性状
Solid
体外研究(In Vitro)
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor with an IC50 of 52 μM in the Alphascreen assay.
NCGC00378430 (20 μM; 3 days) blocks TGF-β induced activation of p-Smad3, upregulation of FN1, and downregulation of E-CAD in T47D cells.
NCGC00378430 (10 μM; 3 days) reverses the Sine oculis homeobox homolog 1 (SIX1)-induced increase in p-SMAD3 and does not alter total E-CAD levels. NCGC00378430 restores membranous E-CAD in MCF7-SIX1 cells, along with inhibiting FN1 expression.
NCGC00378430 (10 or 20 μM) disrupts SIX1-EYA2 interaction in breast cancer cells (MCF7, T47D, MDA-MB-231 cells).
NCGC00378430 (10 μM; for 3 days) partially reverses SIX1-mediated transcriptional and metabolic signatures in MCF7 breast tumor cells.
has not independently confirmed the accuracy of these method
体内研究(In Vivo)
NCGC00378430 (25 mg/kg; local injection to the site of tumor; every other day; from day 3 until the day 21) dramatically decreases distant metastatic burden compared to vehicle treatment.
NCGC00378430 (20 mg/kg; IV) has a T 1/2 α of 0.25 hours.
has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Hengbo Zhou, et al. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Res. 2020 Jun 15;80(12):2689-2702.
溶解度数据
In Vitro: DMSO : 100 mg/mL (226.50 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)
[1]. Hengbo Zhou, et al. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Res. 2020 Jun 15;80(12):2689-2702.

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2